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Abstract
Background: Development of distant metastases involves a complex multistep biological process termed the
invasion-metastasis cascade, which includes dissemination of cancer cells from the primary tumor to secondary
organs. NOTCH developmental signaling plays a critical role in promoting epithelial-to-mesenchymal transition,
tumor stemness, and metastasis. Although all four NOTCH receptors show oncogenic properties, the unique
role of each of these receptors in the sequential stepwise events that typify the invasion-metastasis cascade
remains elusive.
Methods: We have established metastatic xenografts expressing high endogenous levels of NOTCH3 using estrogen
receptor alpha-positive (ERα+) MCF-7 breast cancer cells with constitutive active Raf-1/mitogen-associated protein
kinase (MAPK) signaling (vMCF-7Raf-1) and MDA-MB-231 triple-negative breast cancer (TNBC) cells. The critical role of
NOTCH3 in inducing an invasive phenotype and poor outcome was corroborated in unique TNBC cells resulting from
a patient-derived brain metastasis (TNBC-M25) and in publicly available claudin-low breast tumor specimens collected
from participants in the Molecular Taxonomy of Breast Cancer International Consortium database.
Results: In this study, we identified an association between NOTCH3 expression and development of metastases in
ERα+ and TNBC models. ERα+ breast tumor xenografts with a constitutive active Raf-1/MAPK signaling developed
spontaneous lung metastases through the clonal expansion of cancer cells expressing a NOTCH3 reprogramming
network. Abrogation of NOTCH3 expression significantly reduced the self-renewal and invasive capacity of ex vivo
breast cancer cells, restoring a luminal CD44low/CD24high/ERαhigh phenotype. Forced expression of the mitotic Aurora
kinase A (AURKA), which promotes breast cancer metastases, failed to restore the invasive capacity of NOTCH3-null
cells, demonstrating that NOTCH3 expression is required for an invasive phenotype. Likewise, pharmacologic inhibition
of NOTCH signaling also impaired TNBC cell seeding and metastatic growth. Significantly, the role of aberrant NOTCH3
expression in promoting tumor self-renewal, invasiveness, and poor outcome was corroborated in unique TNBC cells
from a patient-derived brain metastasis and in publicly available claudin-low breast tumor specimens.
Conclusions: These findings demonstrate the key role of NOTCH3 oncogenic signaling in the genesis of breast cancer
metastasis and provide a compelling preclinical rationale for the design of novel therapeutic strategies that will
selectively target NOTCH3 to halt metastatic seeding and to improve the clinical outcomes of patients with breast cancer.
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Background
Breast cancer represents the second leading cause of
cancer death among women worldwide [1]. Each year it
is estimated that over 240,000 women in the United
States will be diagnosed with breast cancer and that
more than 40,000 will die of tumor relapse and meta-
static dissemination to distant organs [2]. Although
breast cancer research has been devoted largely to
characterization of the molecular mechanisms respon-
sible for tumor development, metastatic growth in sec-
ondary organs after surgical eradication of the primary
tumor is responsible for poor outcomes [3]. For this rea-
son, a better understanding of the molecular mecha-
nisms leading to cancer cell seeding and metastatic
growth is imperative to develop innovative therapies that
will selectively target breast tumor metastasis-initiating
cells (BT-MICs) and halt tumor progression.
Several studies have demonstrated that aberrant acti-
vation of mitogen-associated protein kinase (MAPK)
oncogenic signaling induces drug resistance, develop-
ment of distant metastases, and ultimately poor outcome
of patients with breast cancer [4–6]. However, the mo-
lecular mechanisms by which the MAPK signaling path-
way promotes cancer cells seeding and metastatic
dissemination are poorly understood. It has been
established that cross-talk between NOTCH and MAPK
pathways in breast cancer correlates with early tumor re-
lapse and poor overall survival [7], suggesting that
NOTCH developmental signaling is a key mediator of
MAPK-induced metastases. Canonical NOTCH signal-
ing consists of four NOTCH receptors (NOTCH1–4)
and their ligands (Delta-like 1, 3, and 4 and Jagged 1 and
2). All receptors are synthesized as a precursor form
consisting of extracellular, transmembrane, and intracel-
lular subunits [8]. In the most widely accepted model of
NOTCH activation, ligand binding unfolds the negative
regulatory region admitting the second cleavage through
metalloproteinases of the ADAM family [9]. After this,
γ-secretase complex performs an intramembrane cleav-
age releasing the NOTCH intracellular domain that
translocates to the nucleus [10]. Following NOTCH acti-
vation, the hairy and enhancer of split (HES) family and
the hairy-related transcription factor are expressed and
in turn orchestrate the NOTCH-induced nuclear repro-
gramming [11, 12]. Aberrant activation of NOTCH
oncogenic signaling promotes an invasive phenotype
through activation of epithelial-to-mesenchymal
transition (EMT) signaling [13]. Changes during EMT
drive the transition from a polarized epithelial phenotype
to an elongated fibroblastoid-like phenotype that typifies
the morphology of highly metastatic cancer cells. These
cancer cells exhibit a more invasive behavior
characterized by downregulation of epithelial proteins
(E-cadherin and claudin) responsible for cell adhesion
and upregulation of mesenchymal proteins (N-cadherin
and vimentin) involved in cell motility [14]. Several studies
have established that breast cancer cells that undergo
EMT acquire a CD44high/CD24low cancer stemlike pheno-
type characterized by an increased capacity for tumor
self-renewal, drug resistance, and high metastatic procliv-
ity [15–17]. The discovery of breast tumor-initiating cells
(BTICs) with a CD44high/CD24low phenotype has been
critical to elucidating the molecular mechanisms respon-
sible for early recurrence and onset of distant metastases
in advanced breast cancer. The correlation between aber-
rant activation of NOTCH/HES1 stemness signaling and
tumor metastases has been revealed through a series of
experimental investigations [18, 19]. Although all four
NOTCH receptors can increase HES1 expression, whether
a specific NOTCH receptor is mainly responsible for
HES1 overexpression and transcriptional activity during
the early stages of metastatic dissemination has not been
established [20]. Recent findings propose that NOTCH
signaling may promote the early onset of distant metasta-
ses through activation of C-X-C chemokine receptor type
4, a chemokine receptor that plays a key role in fostering
cancer cell seeding to secondary organs [21, 22]. Although
these studies show the redundant activity of NOTCH sig-
naling, individual NOTCH receptors are likely to regulate
breast cancer cells in unique ways; hence, it is essential to
delineate the functional role for specific NOTCH recep-
tors in driving tumor progression. Importantly, the
NOTCH signaling pathway represents a powerful
“druggable target” for cancer stemlike cells, which are
known to be resistant to conventional chemotherapy
and radiation but seem especially sensitive to inhib-
ition of key stem cell pathways [23]. Several classes of
investigational pan-NOTCH inhibitors have been de-
veloped that include γ-secretase inhibitors (GSIs) and
humanized monoclonal antibodies against NOTCH
receptors [24, 25]. Although GSIs have numerous
substrates besides NOTCH receptors, the pharmaco-
logic activity and toxicity of GSIs in vivo appears to
be due largely to NOTCH inhibition [26]. GSIs have
been administered to patients in phase I clinical trials,
either as single agents or in combination with stand-
ard chemotherapy, with promising results [27, 28].
In this study, we demonstrated that NOTCH3 expres-
sion is linked to cancer cell seeding and development of
breast cancer metastases. Using variant estrogen recep-
tor alpha-positive (ERα+ MCF-7) breast tumor xeno-
grafts with constitutive active Raf-1/MAPK signaling
(vMCF-7Raf-1), we showed that metastatic cancer cells
display a clonal origin and increased expression of
NOTCH3 that is required to induce self-renewal, stem-
ness, and high invasive capacity. Significantly, forced ex-
pression of the mitotic Aurora kinase A (AURKA),
which promotes stemness and breast cancer metastases
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[29], failed to restore the invasive capacity of
NOTCH3-null vMCF-7Raf-1 cells, demonstrating that
NOTCH3 oncogenic signaling is downstream of AURKA
and is essential to inducing breast cancer cell invasive-
ness. The role of NOTCH3 expression in inducing a
metastatic phenotype was corroborated in highly inva-
sive MDA-MB-231 triple-negative breast cancer (TNBC)
cells isolated from lung metastases. Moreover, we also
demonstrated the clinical relevance of the NOTCH3 sig-
naling pathway in promoting tumor invasiveness and
poor outcome in unique patient-derived TNBC brain
metastasis and publicly available claudin-low breast
tumor specimens collected from participants of the Mo-
lecular Taxonomy of Breast Cancer International Con-
sortium (METABRIC) database [30]. Taken together,
these findings revealed the critical role of NOTCH3
oncogenic signaling in the genesis of breast cancer me-
tastases and provided a compelling preclinical rationale
for the design of novel therapeutic strategies that will se-
lectively target the NOTCH3 signaling pathway to im-
prove the clinical outcome of patients with advanced
breast cancer.
Methods
Established breast cancer cell lines
The human breast cancer cell lines MCF-7 and
MDA-MB-231 were obtained from the American Type
Culture Collection (Mayo Clinic, Manassas, VA, USA).
The MCF-7 cells overexpressing the Raf-1 oncoprotein
were generated as previously described [29]. Human
mammary epithelial cells (HMEC) were kindly provided
by Wilma Lingle, PhD (Mayo Clinic). All cell lines were
maintained in DMEM containing 5 mM glutamine, 1%
penicillin/streptomycin, 20 μg/ml insulin (only for MCF-7
and their variants), and 10% FBS at 37 °C in a 5% CO2
atmosphere.
Human breast cancer xenografts
Procedures established by the institutional animal care
and use committee based on the National Institutes of
Health Guidelines for the Care and Use of Laboratory An-
imals were followed for all experiments. Four-week-old
nonovariectomized female NCR/Nu/Nu nude mice were
anesthetized by exposure to 3% isoflurane, and five mice
per group were given subcutaneous injections with 2 × 106
MCF-7 or vMCF-7ΔRaf-1 cancer cells suspended in 50 μl
of 50% Matrigel (BD Biosciences, San Jose, CA, USA).
Tumor localization and growth was monitored using an
IVS imaging system (IVS, Coppell, TX, USA) from the
ventral view 10 minutes after luciferin injection. After
12 weeks, mice were killed, and xenograft tumors were
processed for histology and IHC analyses. Animals were
examined every day, and body weight and primary tumor
size were measured at least one or two times per week.
Consistent distress and potential pain (> 1 day) were alle-
viated by killing the mice. If some of the animals were los-
ing more than 10% of their body weight or if blood was
consistently observed in the urine or around the genitals
of the mice, the mice were appropriately killed. When typ-
ical signs of distress, including labored breathing and in-
activity, were consistently observed for > 1 day, the
animals were appropriately killed. When the primary
tumor was > 2 cm, the animals were killed. Animals were
killed using pentobarbital (100 mg/kg intraperitoneally)
followed by cervical dislocation. The Mayo Clinic Institu-
tional Animal Care and Use Committee approved this
study (A00002634-17). Breast tumor xenografts and ex-
perimental lung metastases were established as previously
described [29, 31]. To reestablish cultures from 1GX ex-
plants, primary tumors and metastatic lungs were excised
from killed animals, minced using sterile scissors, and
transferred to complete culture medium, and fibroblast-
free tumor cell lines were established by serial passages in
culture.
Patient-derived TNBC cells
TNBC-M25 cells were isolated from a patient-derived
brain metastasis TNBC xenograft model (EX170416)
that was generated by the Breast Cancer Genome-
Guided Therapy study (BEAUTY) in the Mayo Clinic
(A17713) [32]. To establish cultured TNBC-M25 cells,
patient-derived xenograft model EX170416 was excised
from killed animals, minced using sterile scissors, and
transferred to complete culture medium, and fibroblast-
free TNBC-M25 cells were propagated in culture and
used for this study.
Immunoblot, immunofluorescence, and fluorescence-
activated cell sorting assays
Immunoblot and immunofluorescence assays were per-
formed as previously described [29]. Antibodies
employed to perform these studies were as follows: cen-
trin (20H5 kindly provided by Dr. Salisbury’s laboratory
at the Mayo Clinic); ERα and pericentrin (Santa Cruz
Biotechnology, Dallas, TX, USA); AURKA (Cell Signal-
ing Technology, Danvers, MA, USA); CD44, CD24,
NOTCH1, NOTCH2, and NOTCH3 (Abcam, Cam-
bridge, MA, USA); and β-actin and α-tubulin (Sigma-Al-
drich, St. Louis, MO, USA). Secondary antibodies were
obtained from Molecular Probes (Eugene, OR, USA).
Gene microarray analysis
Total RNA was extracted from basal-like CD24−/low cells
isolated by fluorescence-activated cell sorting (FACS)
from vMCF-7Raf-1 1GX cells as previously described
[29], and mammospheres (MPS) were derived from
vMCF-7Raf-1 1GX-M cells using TRIzol reagent according
to the manufacturer’s instructions (Life Technologies,
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Carlsbad, CA, USA). Total RNA (1 μg; A260/A280 ratio of
1.8–2.2) was used to probe for global genome expression
employing Affymetrix U133 Plus 2.0 chips (Affymetrix,
Santa Clara, CA, USA). Gene network and functional en-
richment analysis was performed employing MetaCore
software (GeneGo, St. Joseph, MI, USA). Two inde-
pendent sets of experiments were performed. The raw
data regarding the transcriptomic analysis can be
accessed in the Gene Expression Omnibus database
(http://www.ncbi.nlm.nih.gov/geo/info/linking.html).
Cytogenetic and spectral karyotyping analysis
Cell harvest and metaphase slide preparation for routine
cytogenetic and spectral karyotyping (SKY) analysis were
performed as previously described [33]. Hybridization,
wash, and detection of the human SKYPaint® probe (Ap-
plied Spectral Imaging, Carlsbad, CA, USA) were per-
formed as recommended by the manufacturer. Image
acquisition and spectral analysis of metaphase cells were
achieved by using the SD200 SpectraCube™ Spectral Im-
aging System (Applied Spectral Imaging) mounted on a
Zeiss Axioplan2 microscope (Carl Zeiss MicroImaging,
Inc., Thornwood, NY, USA). Images were analyzed using
HiSKY analysis software (Applied Spectral Imaging).
Mammosphere formation
Human breast cancer cells were plated in ultralow
attachment 24- and 96-well culture dishes in 100 μl of
MammoCult™ medium (STEMCELL Technologies,
Vancouver, BC, Canada). Medium was added every
2 days for a maximum of 8 days. MPS formation was re-
corded after 24 days through a digital camera (Nikon
Instruments, Melville, NY, USA).
Real-time apoptosis assay
MDA-MB-231 lung metastasis (LM) cells (n = 30,000)
were plated in Costar 12-well plates (Corning Life Sci-
ences, Oneonta, NY, USA) and incubated with YOYO-1
iodide. After 24 hours, cells were treated with 500 nM
alisertib or 500 nM LY-411575 and incubated for add-
itional 24 hours in the presence of YOYO-1 iodide.
Apoptotic cells were quantified in real time using Incu-
Cyte S3 (Essen BioScience, Ann Arbor, MI, USA). Exper-
iments were performed in triplicate (± SD).
Real-time invasion assay
Cancer cell invasion capacity was assessed using 24-well
plate cell culture inserts equipped with a light-tight poly-
ethylene terephthalate membrane (8-μm pore size, Corn-
ing® FluoroBlok™ 351152; Corning Life Sciences). Cancer
cells were starved overnight and labeled with 5 μM Cell
Tracker Red CMTPX (C34552; Thermo Fisher Scientific,
Waltham, MA, USA) for 1 hour. Inserts were placed in
24-well companion plates (353504; Corning Life
Sciences), coated with 150 μl of growth-reduced Matri-
gel matrix (356230; Corning Life Sciences), and incu-
bated for 2 hours at 37 °C. Serum-free medium was used
to seed 500 μl of starved cell suspension into the appro-
priate inserts and incubated at 37 °C for 24 hours. The
cells that had migrated through the membrane were im-
aged and quantified by using a plate-based cell cyt-
ometer (Celigo; Nexcelom Bioscience LLC, Lawrence,
MA, USA). Results are derived from three independent
experiments with comparable outcomes (± SD).
Aldehyde dehydrogenase activity assay
Aldehyde dehydrogenase 1 (ALDH1) activity was
detected by FACS analysis using the ALDEOFLUOR
assay kit (STEMCELL Technologies) according to the
manufacturer‘s instructions [34]. Results are derived
from three independent experiments with comparable
outcomes (± SD).
CRISPR-NOTCH3 breast cancer cells
Two custom small guide RNAs (sgRNAs) for NOTCH3
targeting were designed in silico via the CRISPR design
tool (http://crispr.mit.edu:8079/). sgRNAs were cloned
into an expression plasmid pSpcas9-T2A-GFP carrying
sgRNA scaffold backbone, Cas9, and green fluorescent
protein (GFP). Constructs were verified by sequencing
and then transfected into the cells. GFP-positive cells
were isolated by FACS followed by an expansion period
to establish a polyclonal knockout cell population. To
generate monoclonal cell lines from the polyclonal
population, a limiting serial dilution protocol was used
to seed individual cells in 96-well plates at an average
density of 0.5 cells/well, and plates were kept in an incu-
bator for 2 to 3 weeks. Genomic DNA was extracted
from cells grown as monoclonal populations, and exter-
nal primers were designed in the 5′-flanking region of
sgRNAs (NOTCH3-F1: 5′-GCCAGAGGATTACCAGG
AAGAGAA-3′ and Notch3-R1: 5′-CCCAGGGAA
GGAGGGAGGAG-3′) were used for initial selection of
knockout clones. Internal primers (NOTCH3-F1: 5′-GC
CAGAGGATTACCAGGAAGAGAA-3′ and 5′-GCCA
AGCTGGATTCTGTGTACCTA-3′) were used to verify
prescreened clones, and the intensity of amplified prod-
uct band was used as a marker for knockout efficiency.
(The lower intensity is indicative of higher knockout ef-
ficiency.) Clone 416, which showed the most efficient
NOTCH3 knockout, was selected and expanded, and
NOTCH3 protein expression was assessed by immuno-
blot analysis.
METABRIC analysis
Claudin-low breast tumor specimens were selected from
participants of the METABRIC public database. The
METABRIC database (http://molonc.bccrc.ca/aparicio-
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lab/research/metabric/) contains clinical traits, expression,
copy number variation profiles, and single-nucleotide
polymorphism genotypes derived from patients with
breast cancer [30].
Results
Genomic convergence is linked to clonal expansion of
breast cancer metastatic cells
To investigate in vivo the role of Raf-1/MAPK onco-
genic signaling in the genesis of BT-MICs, we used a
variant MCF-7 cell line expressing a constitutive active
Raf-1 oncoprotein (vMCF-7Raf-1) that has been described
previously [5, 29]. Nude mice carrying vMCF-7Raf-1 xe-
nografts were killed 12 weeks after implantation to iso-
late putative BT-MICs from lung metastatic nodules.
Although animals carrying MCF-7 xenografts did not
develop lung metastases, vMCF-7Raf-1 xenografts gave
rise to lung micrometastatic nodules (Fig. 1a). Because
breast cancer progression is functionally linked to devel-
opment of centrosome amplification, which represents
one of the major driving forces of chromosomal instabil-
ity (CIN) [35, 36], we investigated the centrosome
phenotype in MCF-7, vMCF-7Raf-1, and cancer cells iso-
lated from tumor xenografts (referred to as first gener-
ation derived from xenografts [1GX]) [29]. HMEC were
employed as controls because of their normal centro-
some phenotype. Whereas MCF-7, MCF-7 1GX, and
vMCF-7Raf-1 cells showed a low grade of centrosome
amplification, with the majority of cells harboring two or
four centrioles, centrosome amplification (more than
four centrioles in a single cell) was observed in the inva-
sive vMCF-7Raf-1 1GX cells (Fig. 1b and c), in agreement
with our previous findings [29]. To investigate the extent
to which the degree of centrosome amplification in-
creases during tumor progression, we also cultured
metastatic cancer cells isolated from lung tissue (referred
to as vMCF-7Raf-1 1GX-M). Remarkably, vMCF-7Raf-1
1GX-M cells showed a normal centrosome phenotype
compared with their vMCF-7Raf-1 1GX matching cells
(Fig. 1b and c).
To establish whether loss of centrosome amplification in
vMCF-7Raf-1 1GX-M cells was linked to genomic conver-
gence and restoration of a stable karyotype, we performed
SKY analysis of MCF-7 and their variant vMCF-7Raf-1 cells.
Although MCF-7 and variant vMCF-7Raf-1 cells exhibited
different degrees of structural and numerical chromosomal
abnormalities, vMCF-7Raf-1 1GX-M cells showed the lowest
percentage of numerical chromosomal aberrations (Table 1
and Fig. 2a and b). In view of the fact that aneuploidy in
cancer cells represents the “state,” whereas CIN indicates
the “rate,” of chromosomal aberrations [36], we investigated
the percentage of cells with nonclonal chromosomal abnor-
malities as a measure of CIN in MCF-7 and their variant
vMCF-7Raf-1 cells. Unique chromosomal aberrations were
considered nonclonal if they were present exclusively in
one or two cancer cells (Table 1). Significantly, whereas
nonmetastatic MCF-7 1GX cells showed the highest degree
of CIN, vMCF-7Raf-1 1GX-M cells exhibited only clonal
chromosomal abnormalities (Table 1 and Fig. 2c).
Metastatic cells show increased self-renewal capacity that
is linked to upregulation of NOTCH3 reprogramming
network
To define whether clonal metastatic cancer cells exhib-
ited higher stemness capacity than matching parental
cells, vMCF-7Raf-1, vMCF-7Raf-1 1GX, and vMCF-7Raf-1
1GX-M cells were cultured under nonadherent condi-
tions to test the efficiency of MPS formation that repre-
sents an excellent in vitro surrogate assay of tumor
self-renewal capacity [29]. vMCF-7Raf-1 1GX-M cells
showed the highest number of MPS formations, demon-
strating their increased ability to self-renew compared
with matching parental cells (Fig. 3a and b). Because
breast cancer invasiveness is functionally linked to loss
or reduction of the CD24 epithelial surface marker and
development of an invasive basal-like phenotype [29], we
assessed CD24 expression in breast cancer cells under
nonadherent conditions. Immunofluorescence analysis
showed loss of CD24 expression in MPS derived from
vMCF-7Raf-1 1GX-M cells compared with parental cells
(Additional file 1: Figure S1), demonstrating that loss of
CD24 expression is linked to higher tumor self-renewal
capacity and plasticity of metastatic breast cancer cells.
To identify an exclusive metastatic gene signature that
typifies BT-MICs, we performed a comparative
transcriptomic analysis between basal-like CD24−/low
(isolated by FACS from vMCF-7Raf-1 1GX cells [29]) and
MPS derived from vMCF-7Raf-1 1GX-M (harboring a
CD24−/low phenotype) cells. Using a twofold change gene
expression cutoff, global gene array analysis showed that
211 genes were differentially expressed between CD24−/
low cells and vMCF-7Raf-1 1GX-M MPS (Additional file 2:
Figure S2a). Functional enrichment analysis identified 59
genes involved in nuclear reprogramming that were
overexpressed in vMCF-7Raf-1 1GX-M MPS (Additional
file 2: Figure S2b). Significantly, Ingenuity Pathway Ana-
lysis software (IPA®; QIAGEN Bioinformatics, Redwood
City, CA, USA) uncovered a noncanonical NOTCH3
network that was upregulated exclusively in vMCF-7Raf-1
1GX-M MPS (Fig. 3c and d). The NOTCH3 network in-
cluded nine genes (HES1, FOSB, JUN, EGR1, EGR3,
MYC, TFDP2, ATF3, PGR) encoding for transcription
factors that play a central role in tumor progression
(Fig. 3e and Additional file 3: Figure S3). Immunofluor-
escence analysis showed a higher percentage of
vMCF-7Raf-1 1GX-M cells expressing NOTCH3 than
their matching vMCF-7Raf-1 1GX cells (Fig. 3f ),
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suggesting that NOTCH3-expressing cancer cells exhib-
ited a higher capacity to promote seeding and growth to
distant organs.
NOTCH3 expression is required to induce a CD44high/
CD24low/ERlow breast cancer stemlike phenotype, self-
renewal, and invasive capacity
Because our results indicate that NOTCH3-expressing
cells originate in vMCF-7ΔRaf1 xenografts (Fig. 3f), we
employed the CRISPR-Cas9 gene editing technology to
generate unique NOTCH3-knockout breast cancer cells
(vMCF-7Raf-1 1GXCRISPR-NOTCH3) and assessed their stem-
ness and invasive properties (Additional file 4: Figure S4
and Fig. 4a and b). vMCF-7Raf-1 1GX and vMCF-7Raf-1
1GXCRISPR-NOTCH3 cells were cultured under nonadherent
conditions to test the efficiency of MPS formation.
vMCF-7Raf-1 1GXCRISPR-NOTCH3 cells exhibited a reduction
in the number and size of MPS formation compared with
parental vMCF-7Raf-1 1GX cells (Fig. 4c and d). To define
the extent to which impairment of self-renewal capacity
was linked to suppression of breast cancer stemlike
phenotype, vMCF-7Raf-1 1GX and vMCF-7Raf-1
1GXCRISPR-NOTCH3 MPS were stained for CD44 and CD24
breast cancer stemness markers. vMCF-7Raf-1 1GXCRISPR--
NOTCH3 MPS exhibited a more differentiated CD44low/
CD24high phenotype compared with vMCF-7Raf-1 1GX
MPS that showed a CD44high/CD24low cancer stemlike
phenotype (Fig. 5a and b). Because CD44high/CD24low
breast cancer stemlike cells also lack ERα expression [29,
37], we aimed to assess ERα expression/localization in
vMCF-7Raf-1 1GX and vMCF-7Raf-1 1GXCRISPR-NOTCH3
MPS. Whereas vMCF-7Raf-1 1GX MPS lacked nuclear
ERα expression, partial restoration of nuclear ERα expres-
sion was observed in vMCF-7Raf-1 1GXCRISPR-NOTCH3
MPS (Fig. 5a and d), corroborating the role of the
NOTCH3 signaling pathway in restraining ERα expression
in breast cancer cells [38]. To define the causative role of
NOTCH3 expression in promoting ALDH1 activity that
represents a universal functional marker of tumor stem-
ness, chemoresistance, and metastasis [34, 39], we per-
formed an ALDEOFLUOR assay in vMCF-7Raf-1 1GX and
vMCF-7Raf-1 1GXCRISPR-NOTCH3 cells. Significantly,
vMCF-7Raf-1 1GXCRISPR-NOTCH3 cells showed a reduction
of ALDH1 activity compared with parental vMCF-7Raf-1
Fig. 1 Establishment of metastatic breast cancer xenografts. a Lungs isolated from nude mice carrying MCF-7 and vMCF-7ΔRaf1 tumor xenografts.
Following 12 weeks of growth, animals were killed, and lung tissue was stained with H&E to determine the presence of metastatic nodules. b
Immunofluorescence assay showing representative images of centrioles and pericentriolar material (PCM) in MCF-7 and variant breast cancer cells.
Centrioles were labeled in green with monoclonal 20 h5 centrin antibody, and PCM was labeled in red with polyclonal pericentrin antibody. c
Graph showing the average percentage of cells with more than four centrioles from three independent experiments (± SD). HMEC Human mammary
epithelial cells
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1GX cells (Fig. 5e and f). Last, we aimed to investigate
whether lack of NOTCH3 expression was linked to
an impairment of vMCF-7Raf-1 1GX cells’ invasive
capacity. An in vitro real-time invasion assay showed
that abrogation of NOTCH3 expression significantly
reduced the invasiveness of vMCF-7Raf-1 1GX cells
(Fig. 6a and b). These results were validated in
vMCF-7Raf-1 1GX cells infected with lentiviral short
hairpin RNAs (lenti-shRNAs) targeting NOTCH3
messenger RNAs (mRNAs) that also showed a signifi-
cant impairment of invasive capacity (Fig. 6c–f ).
NOTCH3 expression is necessary to mediate AURKA-
induced invasiveness of breast cancer cells
Because we have previously demonstrated in vMCF-7ΔRaf1
xenografts the causal role of aberrant AURKA activity in
inducing the development of spontaneous lung metastases
[29], we investigated whether NOTCH3 expression was
necessary to mediate AURKA-induced invasive capacity of
vMCF-7ΔRaf1 1GX cells. vMCF-7ΔRaf1 1GX and
vMCF-7Raf-1 1GXCRISPR-NOTCH3 cells were infected with
empty lentiviral vectors (lenti-vectors; used as control)
and lenti-vectors expressing a GFP-tagged AURKA con-
struct (Fig. 7a and b). Endogenous levels of AURKA were
reduced in vMCF-7Raf-1 1GXCRISPR-NOTCH3 cells, whereas
only vMCF-7ΔRaf1 1GX cells expressing GFP-AURKA
showed increased NOTCH3 expression (Fig. 7a–d). These
results demonstrate a positive feedback loop between
AURKA and NOTCH3 oncogenic pathways. To define
whether NOTCH3 expression was essential to mediate
AURKA-induced invasiveness of vMCF-7ΔRaf1 1GX cells,
we performed an in vitro real-time invasion assay. Signifi-
cantly, expression of GFP-AURKA in vMCF-7ΔRaf1 1GX
cells enhanced their invasive capacity (Fig. 7e and f). On
the contrary, expression of GFP-AURKA in vMCF-7Raf-1
1GXCRISPR-NOTCH3 cells failed to restore their invasive
ability (Fig. 7e and f), demonstrating that NOTCH3 ex-
pression is required to mediate AURKA-induced breast
cancer cells’ aggressiveness.
Pharmacologic targeting of NOTCH signaling inhibits
TNBC cell seeding and metastatic growth
To confirm in a different breast cancer model the find-
ing that NOTCH3 expression is restricted to metastatic
cells, we used CD44high/CD24low MDA-MB-231 TNBC
cells isolated from experimental lung metastases
(MDA-MB-231 LM) [37, 40]. MDA-MB-231 LM cells
showed a higher percentage of cells expressing
NOTCH3 than parental MDA-MB-231 cells (Fig. 8a).
To assess the causal role of NOTCH3 expression in pro-
moting the highly invasive capacity of MDA-MB-231
LM cells, we employed an in vitro real-time invasion
assay. MDA-MB-231 LM cells infected with
lenti-shRNAs targeting NOTCH3 significantly reduced
Table 1 Cytogenetic and SKY Analysis of Human Mammary
Epithelial Cells (HMEC) and Breast Cancer Cells: Representation of
Chromosomal changes detected by cytogenetic and SKY analysis in
HMEC, parental and variant MCF-7 cells
Representation of Chromosomal changes detected by cytogenetic and SKY
analysis in HMEC, parental and variant MCF-7 cells
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their invasiveness compared with MDA-MB-231 LM
cells infected with scramble lenti-shRNAs used as con-
trol (Fig. 8b). Next, we aimed to establish whether
pharmacologic targeting of NOTCH signaling inhibits
metastatic seeding and growth of cancer cells overex-
pressing NOTCH3. MDA-MB-231 LM cells were treated
in vitro with 500 nM of LY411575 (pan-NOTCH inhibi-
tor), and MDA-MB-231 LM cells treated with vehicle di-
methyl sulfoxide (DMSO) were used as a control. After
48-hour incubation, treated and control MDA-MB-231
LM cells were washed with PBS and cultured in
drug-free medium for an additional 48 hours. Viable
cells were then injected into the tail vein of
immune-compromised mice to develop experimental
lung metastases as previously described [29]. Whereas
animals injected with DMSO-treated MDA-MB-231 LM
cells developed lung metastases, animals injected with
LY411575-treated MDA-MB-231 LM cells showed
impaired lung metastatic lesions (Fig. 8c). Histopatho-
logic analysis confirmed that whereas lungs isolated
from control animals exhibited metastatic lesions with
several mitotic figures indicative of active proliferating
cancer cells, the alveolar structure of lungs isolated from
LY411575-treated animals was largely preserved (Fig. 8d).
Importantly, because MDA-MB-231 LM and parental
cells showed nominal levels of NOTCH1 and NOTCH2
(Additional file 5: Figure S5a and b), these results sug-
gest that LY411575-mediated inhibition of cancer cell
seeding and metastatic growth was likely associated with
NOTCH3 targeting.
Genetic targeting of NOTCH3 reduces the self-renewal
and invasive capacity of patient-derived brain metastasis
TNBC cells
To validate in primary breast cancer cells the central
role of the NOTCH3 signaling pathway in inducing a
Fig. 2 Spectral karyotyping (SKY) analysis of human breast cancer cells. a Representative structural and numerical chromosomal abnormalities
identified through SKY analysis in MCF-7 and variant breast cancer cells. Normal human mammary epithelial cells (HMEC) were used as controls.
b Graph showing the percentage of total structural and numerical chromosomal abnormalities identified in MCF-7 and variant breast cancer cells
through SKY analysis. c Graph showing the percentage of nonclonal chromosomal abnormalities identified in MCF-7 and variant breast cancer
cells through SKY analysis. Experiments were performed in triplicate with similar results (± SD)
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metastatic phenotype, we developed unique TNBC cells
(TNBC-M25) isolated from a patient-derived brain me-
tastasis xenograft model that was generated by the
BEAUTY trial in the Mayo Clinic [32]. TNBC-M25 cells
showed increased expression of phospho-AURKA and
NOTCH3 compared with MDA-MB-231 cells (Fig. 9a
and b). Significantly, TNBC-M25 cells showed low levels
of NOTCH1 and NOTCH2, suggesting that NOTCH3
expression plays a major role in promoting their meta-
static phenotype (Additional file 6: Figure S6a and b). To
define the causative role of NOTCH3 expression in in-
ducing self-renewal capacity, TNBC-M25 cells were in-
fected with lenti-shRNAs targeting NOTCH3
(TNBC-M25 infected with scramble lenti-shRNAs were
used as a control) and were cultured under nonadher-
ent conditions to test the efficiency of MPS forma-
tion. TNBC-M25 cells infected with lenti-shRNA
NOTCH3 exhibited a significant reduction in the size
of MPS formation compared with control cells (Fig. 9c
and d). To investigate the extent to which impairment
of self-renewal ability was linked to inhibition of inva-
siveness in TNBC-M25 cells with reduced NOTCH3
expression, we employed an in vitro real-time
invasion assay. TNBC-M25 cells infected with
lenti-shRNA NOTCH3 significantly reduced their in-
vasive capacity compared with TNBC-M25 cells in-
fected with scramble lenti-shRNAs used as a control
(Fig. 9c and f ).
Fig. 3 Self-renewal capacity and transcriptomic characterization of metastatic breast cancer cells. a Representative images of light microscopic analysis
showing mammosphere (MPS) formation from vMCF-7ΔRaf1, vMCF-7ΔRaf1 1GX, and vMCF-7ΔRaf1 1GX-M breast cancer cells after 24 days of culture under
nonadherent conditions (three serial passages). b Graph showing the percentage of vMCF-7ΔRaf1, vMCF-7ΔRaf1 1GX, and vMCF-7ΔRaf1 1GX-M breast
cancer cells isolated from MPS after 24 days of culture under nonadherent conditions (three serial passages) from three independent experiments
(± SD). c In Silico comparative gene network analysis between CD24−/low (isolated from vMCF-7Raf-1 1GX cells) and MPS vMCF-7Raf-1 1GX-M cells using
Ingenuity Pathway Analysis software showed upregulation of a noncanonical NOTCH3 reprogramming network that was upregulated in MPS vMCF-
7Raf-1 1GX-M cells. d In silico comparative functional enrichment analysis between CD24−/low (isolated from vMCF-7Raf-1 1GX cells) and MPS vMCF-7Raf-1
1GX-M cells. e Graph showing the difference in the expression of genes identified in the NOTCH3 network between MPS vMCF-7Raf-1 1GX-M and
CD24−/low cells. f Immunofluorescence analysis showing representative images of vMCF-7ΔRaf1 1GX and vMCF-7ΔRaf1 1GX-M cells stained in green with a
NOTCH3 polyclonal antibody. Nuclei were stained in blue with 4′,6-diamidino-2-phenylindole. Graph showing the average of NOTCH3-expressing cells
from three independent experiments (± SD)
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Aberrant NOTCH3 expression is linked to shorter overall
survival of patients with breast cancer
We analyzed the genome sequencing and mRNA-se-
quencing data of specimens from the METABRIC study
[30] to define the linkage between NOTCH3 expression
and overall survival of patients with claudin-low breast
tumors. The claudin-low subgroup analyzed in the
METABRIC study represented a cluster of 125 patients
characterized by 112 TNBC and 13 ER−/PR−/HER2+
specimens, and the average age at diagnosis was 56.9
years. Whereas none of the 125 patients harbored any
deletion or downregulation of NOTCH3, 8 of 117 cases
(6 TNBC and 2 ER−/PR−/HER2+) showed NOTCH3 al-
terations characterized by mRNA upregulation and/or
copy number variations. Cases of death involved 6 pa-
tients with aberrant NOTCH3 expression and 46 pa-
tients without NOTCH3 alterations. Our survival
analysis showed that NOTCH3 expression was signifi-
cantly associated with decreased overall survival (p =
0.0145). Specifically, the average of the overall survival
(calculated for the whole follow-up) was 282.8 months
for the cases without NOTCH3 alterations and
44.8 months for the cases with aberrant NOTCH3
expression (Fig. 10).
Discussion
Development of distant metastases involves a complex
multistep biological process termed the invasion-metas-
tasis cascade, which includes dissemination of cancer
cells from the primary tumor to secondary organs [41].
This process is inefficient because it has been estimated
that less than 1% of cancer cells will be successful in es-
tablishing clinically detectable metastatic lesions [42].
Specifically in breast cancer, BT-MICs must go through
EMT, invade the extracellular matrix, intravasate and
survive in the systemic circulation, extravasate at the
metastatic site, and finally seed in the new microenvir-
onment [42–44]. Importantly, each of these events is
Fig. 4 Molecular characterization of vMCF-7ΔRaf1 1GX cells with abrogated NOTCH3 expression. a Immunoblot assay showing expression of
NOTCH3 in vMCF-7ΔRaf1 1GX and vMCF-7ΔRaf1 1GX/CRISPR-NOTCH3 cancer cells. b Densitometric analysis showing the percentage of NOTCH3
protein level in vMCF-7ΔRaf1 1GX/CRISPR-NOTCH3 cells relative to parental cells. Graph showing the average from three independent experiments
(± SD). c Representative images of light microscopic analysis showing mammosphere (MPS) formation from vMCF-7ΔRaf1 1GX and vMCF-7ΔRaf1
1GX/CRISPR-NOTCH3 cells after 24 days of culture under nonadherent conditions (three serial passages). d Graphs showing the number and the
size of MPS derived from vMCF-7ΔRaf1 1GX and vMCF-7ΔRaf1 1GX/CRISPR-NOTCH3 cells after 24 days of culture under nonadherent conditions
(three serial passages). MPS size was quantified using National Institutes of Health ImageJ software (http://imagej.nih.gov/ij). Graphs show the
average from three independent experiments (± SD)
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driven by the accumulation of genetic and/or epigenetic
alterations within cancer cells necessary for the clonal se-
lection and expansion of BT-MICs that ultimately give rise
to distant metastases [44]. Several lines of evidence sup-
port the hypothesis that BT-MICs might be found within
subpopulations of BTICs [46]. In support of this hypoth-
esis, it has been shown that oncogenic pathways such as
MAPK, AURKA, and NOTCH that induce EMT and ex-
pansion of BTICs also promote onset of distant metasta-
ses [5, 29, 47, 48]. The characterization of the precise role
of each of these oncogenic pathways in the sequential
stepwise events that typify the invasion-metastasis cascade
will be essential for the development of precise thera-
peutic strategies aimed at eradicating distant metastases.
In this study, we uncovered the linkage between
NOTCH3 expression and development of distant metas-
tases in experimental breast cancer models. First, we
used luminal ER+ MCF-7 and variant cells with constitu-
tively active Raf-1/MAPK signaling (vMCF-7ΔRaf1) to es-
tablish in vivo the association between aberrant Raf-1/
MAPK signaling, CIN, and onset of distant metastases.
In agreement with our previous studies [5, 29], only
vMCF-7ΔRaf1 tumor xenografts developed spontaneous
lung metastases, corroborating the causal role of aber-
rant activation of Raf-1/MAPK pathway in promoting
metastatic lesions. Significantly, ex vivo cancer cells iso-
lated from lung metastases (vMCF-7ΔRaf1 1GX-M)
showed a normal centrosome phenotype and clonal
chromosomal aberrations compared with matching
vMCF-7ΔRaf1 1GX parental cells that exhibited centro-
some amplification and nonclonal chromosomal aberra-
tions resulting in CIN. These findings demonstrate in
vivo that loss of centrosome amplification is linked to
restoration of chromosomal stability resulting in the
clonal expansion of metastatic cancer cells. Moreover,
they support the genomic convergence model proposed
for tumor progression in which CIN initially imposed
during tumorigenesis becomes suppressed when cancer
cells have acquired the suitable chromosome composi-
tions and gene dosage that will lead to the successful
Fig. 5 Analysis of breast cancer stemlike phenotype in vMCF-7ΔRaf1 1GX cells with abrogated NOTCH3 expression. a Immunofluorescence analysis
showing representative images of vMCF-7ΔRaf1 1GX and vMCF-7ΔRaf1 1GX/CRISPR-NOTCH3 cells stained in green with a CD44 polyclonal antibody
and in red with a CD24 monoclonal antibody. Nuclei were stained in blue with 4′,6-diamidino-2-phenylindole (DAPI). b Graph showing the average
of cells expressing a CD44+/CD24− phenotype from three independent experiments (± SD). c Immunofluorescence analysis showing representative
images of vMCF-7ΔRaf1 1GX and vMCF-7ΔRaf1 1GX/CRISPR-NOTCH3 cells stained in red with an estrogen receptor alpha (ERα) monoclonal antibody.
Nuclei were stained in blue with DAPI. d Graph showing the average of ERα-positive cells from three independent experiments (± SD). e Fluorescence-
activated cell sorting analysis showing aldehyde dehydrogenase 1 (ALDH1) activity in vMCF-7ΔRaf1 1GX and vMCF-7ΔRaf1 1GX/CRISPR-NOTCH3 cells.
Samples treated with the ALDEOFLUOR inhibitor N,N-diethylaminobenzaldehyde (DEAB) were used as a negative control. f Graph showing
the average of ALDH1+ cells from three independent experiments (± SD)
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establishment of distant metastases [48]. Because it has
been hypothesized that BT-MICs are late stages BTIC
subclones with higher stemness capacity [45], we cul-
tured vMCF-7ΔRaf1 1GX-M and matching vMCF-7ΔRaf1
and vMCF-7ΔRaf1 1GX parental cells under nonadherent
conditions to form MPS as an in vitro surrogate assay of
self-renewal capacity. vMCF-7ΔRaf1 1GX-M cells showed
the highest efficiency in MPS formation compared with
matching parental cells. This increased self-renewal cap-
acity was linked to loss of the CD24 epithelial marker in
vMCF-7ΔRaf1 1GX-M MPS. These results demonstrate
that chromosomal stable vMCF-7ΔRaf1 1GX-M cells have
acquired higher self-renewal and CD24−/low basal-like
plasticity that plays a critical role in EMT, cancer cell
seeding, and metastatic growth to secondary organs [29].
Next, we wanted to establish whether chromosomal sta-
bility and high self-renewal capacity of vMCF-7ΔRaf1
1GX-M cells was linked to an exclusive metastatic signa-
ture. To answer this question, we performed unbiased
comparative transcriptomic and functional gene enrich-
ment analyses between MPS vMCF-7ΔRaf1 1GX-M (that
show CD24−/low) and highly invasive CD24−/low
basal-like cells isolated from matching vMCF-7ΔRaf1
tumor xenografts as previously demonstrated [29]. Func-
tional gene enrichment analysis identified a noncanoni-
cal NOTCH3 reprogramming network that was
upregulated in vMCF-7ΔRaf1 1GX-M MPS. The
NOTCH3 network comprised nine genes encoding for
transcriptional factors with high oncogenic activity
(HES1, FOSB, JUN, EGR1, EGR3, MYC, TFDP2, ATF3,
PGR). This reprogramming network included the
NOTCH downstream target HES1, suggesting that
NOTCH3/HES1 stemness signaling may play a central
role in promoting the survival and seeding of BT-MICs
to secondary organs. Because detection of cancer cell
seeding to secondary organs and onset of micrometas-
tases is clinically challenging, expression of the
NOTCH3 metastatic signature in circulating tumor cells
may have promising clinical relevance in predicting early
onset of distant metastases in patients with breast can-
cer. Importantly, the majority of vMCF-7ΔRaf1 1GX-M
cells were strongly positive for NOTCH3 staining by
Fig. 6 Invasive capacity of vMCF-7ΔRaf1 1GX cells with abrogated NOTCH3 expression. a In vitro real-time invasion assay of vMCF-7ΔRaf1 1GX and
vMCF-7ΔRaf1 1GX/CRISPR-NOTCH3 cells stained in red with 5 μM Cell Tracker Red CMTPX. b Graph showing the average number of invasive cells
from three independent experiments (± SD). c Immunoblot assay showing NOTCH3 expression in vMCF-7ΔRaf1 1GX cells infected with scramble
lentivirus short hairpin RNA (lenti-shRNA; control) and lenti-shRNAs targeting NOTCH3 messenger RNA (mRNA). d Densitometric analysis showing
the percentage of NOTCH3 protein level in vMCF-7ΔRaf1 1GX/shRNA-NOTCH3 cells relative to control. Graph showing the average from three
independent experiments (± SD). e In vitro real-time invasion assay of vMCF-7ΔRaf1 1GX cells infected with scramble lenti-shRNAs (control) and
lenti-shRNAs targeting NOTCH3 mRNA. f Graph showing the average number of invasive cells from three independent experiments (± SD)
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immunofluorescence assay, demonstrating that
NOTCH3 expression was restricted to clonal metastatic
breast cancer cells. vMCF-7ΔRaf1 1GX xenografts exhibit-
ing CIN showed tumor cell heterogeneity for NOTCH3
expression, indicating that NOTCH3high-expressing sub-
clones may arise from the primary tumor and promote
distant metastasis owing to their higher stemness cap-
acity, in agreement with the recent finding that meta-
static clones disseminate early from primary breast
tumors [49]. On the basis of these results, we developed
unique NOTCH3-knockout breast cancer cells
(vMCF-7Raf-1 1GXCRISPR-NOTCH3) to abrogate NOTCH3
expression and evaluate the causative role of NOTCH3
signaling in promoting stemness and invasive properties
of vMCF-7ΔRaf1 1GX cells. NOTCH3 expression was re-
quired to induce in vitro self-renewal capacity and a
CD44high/CD24low breast cancer stemlike phenotype in
vMCF-7ΔRaf1 1GX cells. Because we and others have
demonstrated that CD44high/CD24low BTICs also show
an ERαlow/− basal-like phenotype [29, 37, 38], we
assessed ERα in MPS derived from vMCF-7Raf-1
1GXCRISPR-NOTCH3 and parental cells. Whereas MPS de-
rived from vMCF-7Raf-1 1GX cells lacked ERα expres-
sion, MPS resulting from vMCF-7Raf-1
1GXCRISPR-NOTCH3 cells exhibited restoration of ERα ex-
pression, compatible with previous studies that demon-
strated the role of NOTCH3 signaling in suppressing
ERα expression [38]. Because high ALDH1 activity has
been linked to stemness, early onset of distant metasta-
ses, and poor prognosis in breast cancer [39], we per-
formed an ALDEOFLUOR assay that accurately
identifies highly tumorigenic cancer cells with elevated
Fig. 7 Invasive capacity of vMCF-7ΔRaf1 1GX cells expressing a green fluorescent protein (GFP)-tagged kinase Aurora kinase A (AURKA) construct. a
Immunoblot assay showing expression of endogenous and GFP-tagged AURKA in vMCF-7ΔRaf1 1GX and vMCF-7ΔRaf1 1GX/CRISPR-NOTCH3 cells. b
Densitometric analysis showing the percentage of endogenous AURKA protein levels in vMCF-7ΔRaf1 1GX and vMCF-7ΔRaf1 1GX/CRISPR-NOTCH3
cells relative to control. Graph shows the average from three independent experiments (± SD). c Immunoblot assay showing NOTCH3 protein
levels in vMCF-7ΔRaf1 1GX and vMCF-7ΔRaf1 1GX/CRISPR-NOTCH3 cells expressing empty lentiviral vectors (control) and lentiviral GFP-tagged
AURKA vectors. d Densitometric analysis showing the percentage of NOTCH3 protein levels in vMCF-7ΔRaf1 1GX and vMCF-7ΔRaf1 1GX/shRNA-
NOTCH3 cells relative to vMCF-7ΔRaf1 1GX cells infected with empty lentiviral vectors (control). Graph shows the average from three independent
experiments (± SD). e In vitro real-time invasion assay of vMCF-7ΔRaf1 1GX and vMCF-7ΔRaf1 1GX/CRISPR-NOTCH3 cells expressing empty lentiviral
vectors (control) and lentiviral GFP-tagged AURKA vectors. f Graph showing the average number of invasive cells from three independent experiments (± SD)
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ALDH1 activity. Importantly, vMCF-7Raf-1 1GXCRISPR--
NOTCH3 cells showed minimal ALDH1 activity compared
with parental vMCF-7Raf-1 1GX cells, supporting the role
of NOTCH stemness signaling in inducing ALDH1 ac-
tivity and an increased metastatic behavior [50]. Next,
we defined whether inhibition of self-renewal capacity
and tumor stemness was functionally linked to loss of
invasive capacity. An in vitro real-time invasion assay
showed that abrogation of NOTCH3 expression signifi-
cantly inhibited the invasive capacity of vMCF-7Raf-1
1GX cells, indicating that NOTCH3 signaling pathway is
necessary to promote a more aggressive phenotype. Be-
cause we have previously demonstrated the causative
role of aberrant AURKA activity in driving the develop-
ment of breast cancer metastases [29], we aimed to es-
tablish whether NOTCH3 expression was required to
mediate AURKA-induced highly invasive capacity of
vMCF-7ΔRaf1 1GX cells. Forced expression of AURKA in
vMCF-7ΔRaf1 1GX cells increased NOTCH3 expression
and their in vitro invasive capacity. Conversely, AURKA
overexpression in vMCF-7Raf-1 1GXCRISPR-NOTCH3 cells
failed to restore a highly invasive phenotype, demon-
strating that NOTCH3 expression is required to mediate
AURKA-induced high metastatic potential. Moreover,
these results highlight a novel mechanistic linkage be-
tween AURKA and NOTCH3 oncogenic pathways that
is critical to development of a fully metastatic phenotype
in breast cancer cells. To define in a different breast can-
cer model whether increased expression of NOTCH3
was restricted to metastatic cancer cells, we employed
MDA-MB-231 TNBC cells that exhibit a CD44high/
CD24low basal-like phenotype and elevated endogenous
MAPK activity [34, 52]. Significantly, the percentage of
ex vivo MDA-MB-231 cells isolated from lung
Fig. 8 Pharmacologic targeting of NOTCH signaling in triple-negative breast cancer (TNBC) cells. a Immunofluorescence analysis showing
representative images of MDA-MB-231 and MDA-MB-231 lung metastasis (LM) TNBC cells stained in green with a NOTCH3 polyclonal antibody.
Nuclei are stained in blue with 4′,6-diamidino-2-phenylindole (DAPI). Graph shows the average number of NOTCH3-expressing cells from three
independent experiments (± SD). b In vitro real-time invasion assay of MDA-MB-231 LM TNBC cells infected with scramble lentivirus short hairpin
RNAs (lenti-shRNAs; control) and lenti-shRNAs targeting NOTCH3 messenger RNA. Graph shows the average number of invasive cells from three
independent experiments (± SD). c Experimental lung metastasis imaging in live animals of LY-411575-treated or dimethyl sulfoxide (DMSO)-
treated MDA-MB-231 LM cells expressing the firefly luciferase reporter lentivector after tail vein injection. d Lungs isolated from nude mice that
were injected with LY-411575-treated or DMSO-treated MDA-MB-231 LM TNBC cells. Following 4 weeks of growth, animals were killed, and lung
tissues were stained with H&E to determine the presence of metastatic lesions as previously described [29]
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metastases (MDA-MB-231 LM) expressing NOTCH3 was
higher than matching MDA-MB-231 parental cells, sug-
gesting that NOTCH3 signaling is also required for the
metastatic seeding and growth of TNBC cells. These re-
sults are in agreement with a recent study that demon-
strated the role of the NOTCH3 signaling pathway in
promoting the growth of basal-like breast cancer cells
[51–53]. Complementary to our vMCF-7Raf-1 model, tar-
geting of NOTCH3 impaired the in vitro invasive capacity
of MDA-MB-231 LM cells, demonstrating the key role of
NOTCH3 expression in promoting the TNBC highly inva-
sive phenotype. Next, we aimed to determine whether in-
hibition of NOTCH signaling decreased the metastatic
capacity of MDA-MB-231 LM cells. In vitro treatment of
MDA-MB-231 LM cells with the pan-NOTCH inhibitor
LY-411575 resulted in the inhibition of cancer cell seeding
and onset of experimental lung metastases, demonstrating
that NOTCH pharmacologic targeting interferes with late
stages of the invasion-metastasis cascade in NOTCH3-ex-
pressing breast cancer cells. Importantly, MDA-MB-231
LM and matching parental cells expressed nominal levels
of NOTCH1 and NOTCH2, suggesting that LY411575-
mediated inhibition of cancer cell seeding and metastatic
growth was primarily linked to inhibition of the NOTCH3
signaling pathway.
Owing to the limited translatability of established can-
cer cells, and to corroborate the central role of
NOTCH3 in driving a metastatic phenotype in clinically
relevant models, we established unique TNBC cells
(TNBC-M25) isolated from a patient-derived brain me-
tastasis xenograft model. TNBC-M25 cells showed high
expression of phospho-AURKA and NOTCH3, whereas
NOTCH1 and NOTCH2 levels were low, suggesting that
the AURKA/NOTCH3 oncogenic axis plays a major role
Fig. 9 Self-renewal and invasive capacity of patient-derived triple-negative breast cancer (TNBC) cells. a Immunoblot assay showing total Aurora
kinase A (AURKA), phosphorylated AURKA (p~AURKA), and NOTCH3 expression in MDA-MB-231 and patient-derived TNBC-M25 cells. b Densitometry
analysis showing the percentage of p~AURKA and NOTCH3 protein levels in TNBC-M25 cells relative to MDA-MB-231 cells. Graph shows the average
from three independent experiments (± SD). c Representative images of light microscopic analysis showing single-cell dilution tertiary mammosphere
(MPS) from TNBC-M25 cells infected with scramble lentiviral short hairpin RNAs (lenti-shRNAs; control) and lenti-shRNAs targeting NOTCH3 messenger
RNA (mRNA). d Graphs showing the average size from three independent experiments (± SD) of tertiary MPS derived from TNBC-M25 cells infected
with scramble lenti-shRNAs (control) and lenti-shRNAs targeting NOTCH3 mRNA. MPS size was quantified using the National Institutes of Health
ImageJ software (http://imagej.nih.gov/ij). e In vitro real-time invasion assay of TNBC-M25 cells infected with scramble lenti-shRNAs
(control) and lenti-shRNAs targeting NOTCH3 mRNA. f Graph showing the average number of invasive cells from three independent experiments (± SD)
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in promoting their metastatic phenotype. To test this hy-
pothesis, we reduced NOTCH3 expression by
lenti-shRNAs in TNBC-M25 cells. Reduction of NOTCH3
expression impaired self-renewal capacity, resulting in a
significant shrinkage of TNBC-M25 MPS, confirming the
essential role of the NOTCH3 signaling pathway in pro-
moting tumor stemness. Moreover, inhibition of
NOTCH3 expression also reduced in vitro the invasive-
ness of TNBC-M25 cells. These results validated our find-
ings in vMCF-7ΔRaf1 1GX cells that the NOTCH3
signaling pathway is downstream of AURKA and is re-
quired to promote breast cancer cells’ aggressiveness.
Finally, our findings in established and patient-derived
breast cancer cells led us to analyze the correlation be-
tween aberrant expression of NOTCH3 and the overall
survival of patients with claudin-low breast tumors using
copy number aberrations, somatic mutations, and gene
expression data derived from the METABRIC study [30].
We selected claudin-low breast tumors because they
represent a molecular subtype of breast cancer with high
metastatic proclivity and poor outcome originally identi-
fied by gene expression profiling [40]. The claudin-low
subgroup analyzed represented a cluster of 125 patients
characterized by 112 TNBC and 13 ER−/PR−/HER2+
specimens. Our analysis showed that aberrant NOTCH3
expression was significantly associated with decreased
overall patient survival, supporting the pivotal role of
NOTCH3 oncogenic pathway in promoting breast can-
cer progression.
Conclusions
On the basis of our previous studies [5, 29, 34] and the
results presented here, we propose a novel model of
breast cancer progression. Primary breast tumors are
comprised of heterogeneous subclones where bulk can-
cer cells exhibit a nontumorigenic AURKAlow/NOT-
CH3low phenotype that lacks EMT, stemness activity,
and invasive and metastatic capacity. Increased expres-
sion and activation of AURKA will induce EMT and the
genesis of AURKAhigh/NOTCH3low BTIC subclones, and
it is unlikely that these subclones will be competent to
complete the invasion-metastasis cascade, owing to their
limitations in high self-renewal/invasive capacity and
seeding in a new microenvironment. Gain of aberrant
activation of NOTCH3 oncogenic pathway among
BTICs will lead to the clonal expansion of AURKA-
high/NOTCH3high BT-MICs that have acquired strong
stemness properties and the capacity to successfully
complete the invasion-metastasis cascade. Con-
versely, pharmacologic inhibition of NOTCH3
signaling inhibits AURKAhigh/NOTCH3high BT-MIC
seeding to secondary organs and metastatic growth
(Fig. 11). Because we identified a novel cross-talk be-
tween AURKA and NOTCH3 oncogenic pathways in
Fig. 10 Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) analysis of claudin-low triple-negative breast cancer (TNBC)
patients. The claudin-low subgroup analyzed in the METABRIC study represented a cluster of 125 patients characterized by 112 TNBC and 13 ER−/
PR−/HER2+ specimens, and the average of age at diagnosis was 56.9 years. NOTCH3 alterations characterized by messenger RNA upregulation
and/or copy number variations were detected in 8 of 117 cases (6 TNBC and 2 ER−/PR−/HER2+). Cases of death involved 6 patients with aberrant
NOTCH3 expression and 46 patients without NOTCH3 alterations. Survival analysis showed that NOTCH3 expression was significantly associated
with decreased overall survival (p = 0.0145)
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promoting breast cancer progression, we speculate
that dual-targeted therapy with selective inhibitors of
AURKA and NOTCH3 could also represent a novel
stemness-targeted therapeutic strategy to successfully
eradicate BT-MICs, particularly for the clinical man-
agement of highly aggressive TNBCs that currently
lack effective U.S. Food and Drug Administration-ap-
proved targeted therapies.
Additional files
Additional file 1: Figure S1. Expression of CD24 luminal marker in
MPS derived from variant vMCF-7ΔRaf1 and vMCF-7ΔRaf1 1GX-M cells. a
Immunofluorescence analysis showing representative images of vMCF-
7ΔRaf1 and vMCF-7ΔRaf1 1GX-M MPS stained in red with a CD24 monoclonal
antibody. Nuclei were stained in blue with 4′,6-diamidino-2-phenylindole
(DAPI). b Graph showing the average number of CD24-expressing cells from
three independent experiments (± SD). (TIFF 6168 kb)
Additional file 2: Figure S2. Transcriptomic characterization of
metastatic breast cancer cells. a Comparative global gene array analysis
between CD24−/low (isolated by FACS sorting from vMCF-7Raf-1 1GX cells)
and vMCF-7Raf-1 1GX-M MPS. b In silico comparative functional enrichment
analysis between CD24−/low (isolated from vMCF-7Raf-1 1GX cells) and vMCF-
7Raf-1 1GX-M MPS identified 59 genes involved in nuclear reprograming.
(TIFF 6168 kb)
Additional file 3: Figure S3. Expression of genes identified in NOTCH3
metastatic network. Graphs showing the average expression values in
sample replicates (from two independent experiments ± SD) for each
gene represented in the NOTCH3 metastatic network. (TIFF 6168 kb)
Additional file 4: Figure S4. CRISPR-NOTCH3 breast cancer cells. a
NOTCH3 gene knockout using CRISPR/Cas9. Lightning bolt symbols
indicate the targeted gene double-stranded break (DSB) sites for different
sgRNAs F1 and R2. Horizontal arrows show the PCR primers designed at
different chromosomal sites to identify deletions. b A PCR product of ~ 650-
bp size is amplified upon a successful double-hit by SRISPR/Cas9 system. c
Secondary screening using internal primers. Internal primers were used to
screen for clones with efficient gene knockout. Clone 416 was selected for
further verification by immunoblot assay (Fig. 4a). (TIFF 6168 kb)
Additional file 5: Figure S5. NOTCH1 and NOTCH2 expression in TNBC
cells. a Immunofluorescence analysis showing representative images of
MDA-MB-231 and MDA-MB-231 LM TNBC cells stained in green with
NOTCH1 and NOTCH2 polyclonal antibodies. Nuclei were stained in blue
with DAPI. b Graphs showing the average number of NOTCH1- and
NOTCH2-expressing cells from three independent experiments (± SD).
(TIFF 6168 kb)
Additional file 6: Figure S6. NOTCH1 and NOTCH2 expression in
patient-derived TNBC cells. a Immunoblot assay showing NOTCH1 and
NOTCH2 expression in MDA-MB-231 and patient-derived TNBC-M25 cells.
b Densitometric analysis showing the percentage of NOTCH1 and
NOTCH2 protein levels in TNBC-M25 cells relative to MDA-MB-231 cells.
Graph showing the average from three independent experiments (± SD).
(TIFF 6168 kb)
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